Onaolapo, A. Y., & Onaolapo, O. J. (2021). Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule. World journal of psychiatry, 11(7), 297–315. https://doi.org/10.5498/wjp.v11.i7.297

Appalachian State University

MAOIs inhibit the breakdown of the enzyme that breaks down monoamine neurotransmitters. Some MAOIs have antidepressant effects, including:

- Phenelzine (Nardil)
- Isocarboxazid (Marplan)
- Tranylcypromine (Parnate)

Monoamine Oxidase Inhibitors (MAOIs)

Dietary Restrictions with Monoamine Oxidase Inhibitors (MAOIs)

Rege, S. (2023, April 17). Monoamine Oxidase Inhibitor (MAOI) - Mechanism of Action| Psychopharmacology |Clinical Application. Psych Scene hub. https://psychscenehub.com/psychinsights/maoi-psychopharmacology/

Dietary Restrictions with Monoamine Oxidase Inhibitors (MAOIs) Reference

References for secondary mechanisms of MA antidepressants

Monoamine antidepressants convey secondary mechanisms that may alter gut microbiota and glutamate to impact MDD symptoms. MDD is associated with elevated glutamate levels in the frontal cortex. These antidepressants work to reduce glutamate signaling to prevent excitotoxicity. This effectively reduced NMDA functioning, increases AMPA signaling, which leads to BDNF production. In MDD, typically low BDNF levels are seen; this mechanism works to reverse this and attempt to effectively treat MDD.

Learn Before

Related

Learn After